A semisynthetic glycoconjugate provides expanded cross-serotype protection 
against Streptococcus pneumoniae

Kaplonek, Paulina; Yao, Ling; Reppe, Katrin; Voß, Franziska; Kohler, Thomas; Ebner, Friederike; Schäfer, Alexander; Blohm, Ulrike; Priegue, Patricia; Bräutigam, Maria; Pereira, Claney Lebev; Parameswarappa, Sharavathi Guddehalli; Emmadi, Madhu; Ménová, Petra; Witzenrath, Martin; Hammerschmidt, Sven; Hartmann, Susanne; Sander, Leif E.; Seeberger, Peter H.

doi:10.1016/j.vaccine.2021.12.068

Item

ITEM ACTIONSEXPORT

Add to Basket

Local TagsRelease HistoryDetailsSummary

Released

Journal Article

A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae

MPS-Authors

/persons/resource/persons203549

Kaplonek, Paulina
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons268736

Yao, Ling
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons251980

Priegue, Patricia
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons239941

Bräutigam, Maria
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121719

Pereira, Claney Lebev
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons188901

Parameswarappa, Sharavathi Guddehalli
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons209014

Emmadi, Madhu
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons200004

Ménová, Petra
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

/persons/resource/persons121849

Seeberger, Peter H.
Peter H. Seeberger - Vaccine Development, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society;

External Resource

No external resources are shared

Fulltext (restricted access)

There are currently no full texts shared for your IP range.

Fulltext (public)

Preprint.pdf
(Preprint), 528KB

Supplementary Material (public)

There is no public supplementary material available

Citation

Kaplonek, P., Yao, L., Reppe, K., Voß, F., Kohler, T., Ebner, F., et al. (2022). A semisynthetic glycoconjugate provides expanded cross-serotype protection against Streptococcus pneumoniae. Vaccine. doi:10.1016/j.vaccine.2021.12.068.

Cite as: https://hdl.handle.net/21.11116/0000-0009-D251-E

Abstract

Streptococcus pneumoniae (S. pneumoniae) infections are the leading cause of child mortality globally. Current vaccines fail to induce a protective immune response towards a conserved part of the pathogen, resulting in new serotypes causing disease. Therefore, new vaccine strategies are urgently needed. Described is a two-pronged approach combining S. pneumoniae proteins, pneumolysin (Ply) and pneumococcal surface protein A (PspA), with a precisely defined synthetic oligosaccharide, whereby the carrier protein acts as a serotype-independent antigen to provide additional protection. Proof of concept in mice and swine models revealed that the conjugates inhibited colonization of the nasopharynx, decreased the bacterial load and reduced disease severity in the bacteria challenge model. Immunization of piglets provided the first evidence for the immunogenicity and protective potential of synthetic glycoconjugate vaccine in a large animal model. A combination of synthetic oligosaccharides with proteins from the target pathogen opens the path to create broadly cross-protective (“universal”) pneumococcal vaccines.